KPV : données probantes, mécanisme et limites

KPV (lysine-proline-valine) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), corresponding to residues 11 to 13. Researchers have described anti-inflammatory effects for melanocortin peptides such as alpha-MSH, and studies of KPV ask whether this short fragment keeps some of them.

KPV is not an approved medicine in the United States or Canada.

In two mouse models of colitis, KPV reduced inflammation. It still protected mice whose melanocortin-1 receptor does not function, which suggests it acts at least partly independently of that receptor.

In human intestinal and immune cell lines, KPV entered cells through the peptide transporter PepT1, inhibited NF-kappaB and MAP kinase inflammatory signaling, and reduced the release of pro-inflammatory cytokines. Given in drinking water, it reduced chemically induced colitis in mice.

A third study, in a mouse model of colitis-associated cancer, reported that KPV prevented tumor formation in normal mice but had no such effect in mice lacking PepT1. This is a mouse result, not clinical evidence.

None of the cited sources is a human study. FDA states that it has not identified any human exposure data on drug products containing KPV given by any route. Benefits in people with inflammatory bowel disease, skin conditions or any other condition are therefore not established.

Two of the three cited papers share a senior author, so independent replication is limited. None of these findings has been tested in people.

Human safety is unknown. FDA says it lacks important information about any safety issues raised by KPV, including whether it would cause harm if given to humans. No human adverse event data exist among the sources, and long-term effects have not been studied.

KPV is not approved as a therapeutic by the FDA or Health Canada. It appears on FDA's list of bulk drug substances that may present significant safety risks. The 2026 WADA Prohibited List does not name KPV. Its S0 section covers any pharmacological substance not addressed elsewhere on the list and with no current approval by any government health authority for human therapeutic use.